Cannara Biotech (8CB0) Stock Statistics & Valuation Metrics
Total Valuation
Cannara Biotech has a market cap or net worth of EUR 128.82M. The enterprise value is EUR 183.06M.
- Market Cap
- EUR 128.82M
- Enterprise Value
- EUR 183.06M
Share Statistics
Cannara Biotech has 98,782,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 98,782,150
- Owned by Insiders
- 75.64%
- Owned by Institutions
- 0.27%
Financial Efficiency
Cannara Biotech’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 10.86%.
- Return on Equity (ROE)
- 0.13
- Return on Assets (ROA)
- 0.08
- Return on Invested Capital (ROIC)
- 10.86%
- Return on Capital Employed (ROCE)
- 0.17
- Revenue Per Employee
- 237.43K
- Profits Per Employee
- 28.93K
- Employee Count
- 452
- Asset Turnover
- 0.64
- Inventory Turnover
- 1.35
Valuation Ratios
The current PE Ratio of Cannara Biotech is 18.31. Cannara Biotech’s PEG ratio is -0.52.
- PE Ratio
- 18.31
- PS Ratio
- 1.74
- PB Ratio
- 1.63
- Price to FCF
- 43.38
- Price to Operating Cash Flow
- 11.13
- PEG Ratio
- -0.52
Income Statement
In the last 12 months, Cannara Biotech had revenue of 107.32M and earned 13.08M in profits. Earnings per share was 0.14.
- Revenue
- 107.32M
- Gross Profit
- 47.22M
- Operating Income
- 22.20M
- Pretax Income
- 18.10M
- Net Income
- 13.08M
- EBITDA
- 28.46M
- Earnings Per Share (EPS)
- 0.14
Cash Flow
In the last 12 months, operating cash flow was 18.46M and capital expenditures -13.72M, giving a free cash flow of 4.74M billion.
- Operating Cash Flow
- 18.46M
- Free Cash Flow
- 4.74M
- Free Cash Flow per Share
- 0.05
Dividends & Yields
Cannara Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.28%
- Earnings Yield
- 5.23%
Stock Price Statistics
- Beta
- 0.31
- 52-Week Price Change
- 31.00%
- 50-Day Moving Average
- 1.25
- 200-Day Moving Average
- 1.12
- Relative Strength Index (RSI)
- 60.86
- Average Volume (3m)
- 761
Important Dates
Cannara Biotech upcoming earnings date is Nov 24, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Jul 15, 2026
- Next Earnings Date
- Nov 24, 2026
- Ex-Dividend Date
- ―
Financial Position
Cannara Biotech as a current ratio of 2.40, with Debt / Equity ratio of 40.68%
- Current Ratio
- 2.40
- Quick Ratio
- 1.10
- Debt to Market Cap
- 0.25
- Net Debt to EBITDA
- 0.96
- Interest Coverage Ratio
- 5.10
Taxes
In the past 12 months, Cannara Biotech has paid 5.02M in taxes.
- Income Tax
- 5.02M
- Effective Tax Rate
- 0.28
Enterprise Valuation
Cannara Biotech EV to EBITDA ratio is 14.48, with an EV/FCF ratio of 47.01.
- EV to Sales
- 1.89
- EV to EBITDA
- 14.48
- EV to Free Cash Flow
- 47.01
- EV to Operating Cash Flow
- 12.06
Balance Sheet
Cannara Biotech has EUR 21.81M in cash and marketable securities with EUR 37.00M in debt, giving a net cash position of -EUR 15.19M billion.
- Cash & Marketable Securities
- EUR 21.81M
- Total Debt
- EUR 37.00M
- Net Cash
- -EUR 15.19M
- Net Cash Per Share
- -EUR 0.15
- Tangible Book Value Per Share
- EUR 1.25
Margins
Gross margin is 26.30%, with operating margin of 0.10%, and net profit margin of 9.22%.
- Gross Margin
- 26.30%
- Operating Margin
- 0.10%
- Pretax Margin
- 13.82%
- Net Profit Margin
- 9.22%
- EBITDA Margin
- 13.06%
- EBIT Margin
- 7.33%
Analyst Forecast
The average price target for Cannara Biotech is EUR 1.91, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 1.91
- Price Target Upside
- 45.83% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 7.66%
- EPS Growth Forecast
- -37.59%
